LOS ANGELES — Patients with intracranial aneurysm who respond poorly to the antiplatelet drug clopidogrel when treated with flow diversion using the Pipeline embolization device (Medtronic) have ...

Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate ...

The document follows two earlier consensus documents, released in 2013 and 2016. Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), senior author of the paper, ...

The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn't answer any of the key questions about the ...

Although switching from clopidogrel to the more potent antiplatelet agent prasugrel generally eliminates high on-treatment platelet reactivity in stable patients following percutaneous coronary ...

Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet ...

June 6, 2012 (Munich, Germany) — A new substudy of the ISAR-REACT-4 trial has found that those patients with high on-clopidogrel-treatment platelet reactivity (HPR) randomized to bivalirudin (Angiomax ...

WATERTOWN, Mass., April 6, 2026 /PRNewswire/ -- PlateletDiagnostics, LLC (PlateletDx.com) today announced the development of a first-in-class platelet function assay that measures phosphorylation of ...

Please provide your email address to receive an email when new articles are posted on . Clopidogrel is often the antiplatelet agent of choice for patients with ACS or those receiving a stent because, ...

Current platelet function assays rely on light transmission aggregometry or proprietary cartridge-based systems, which require specialized expertise, dedicated instruments, and expensive consumables ...